Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type Colorectal Cancer in First-line Treatment: a Prospective, Observational Multi-centre Study in Spain. PERSEIDA Study

NCT02792478 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02792478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02792478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type Colorectal Cancer in First-line Treatment: a Prospective, Observational Multi-centre Study in Spain. PERSEIDA Study
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
May 6, 2016
Completion date
May 31, 2021
Enrollment
238 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ras wild type mcrc